MeSH term
Frequency | Condition_Probility | DNA, Neoplasm/analysis | 11 | 1.0 |
Humans | 443 | 0.0 |
Immunohistochemistry | 27 | 0.0 |
In Situ Hybridization, Fluorescence | 13 | 0.0 |
Sensitivity and Specificity | 3 | 0.0 |
Adult | 181 | 0.0 |
Alleles | 26 | 0.0 |
Exons | 32 | 0.0 |
Female | 180 | 0.0 |
Fertilization in Vitro | 2 | 1.0 |
Male | 189 | 0.0 |
Neurofibromatosis 2/*diagnosis/genetics | 8 | 100.0 |
Polymerase Chain Reaction | 49 | 0.0 |
*Preimplantation Diagnosis | 3 | 20.0 |
Biopsy | 6 | 0.0 |
DNA Mutational Analysis | 41 | 0.0 |
Genes, Neurofibromatosis 2 | 22 | 88.0 |
Mutation | 45 | 0.0 |
Polymorphism, Genetic | 13 | 0.0 |
Polymorphism, Single-Stranded Conformational | 38 | 1.0 |
Sequence Analysis, DNA | 21 | 0.0 |
Adolescent | 100 | 0.0 |
Child | 71 | 0.0 |
Microscopy, Electron | 4 | 0.0 |
Neurofibromatosis 2/*genetics/*pathology | 4 | 100.0 |
Peripheral Nerves/pathology | 2 | 9.0 |
RNA Splicing/genetics | 3 | 2.0 |
Research Support, Non-U.S. Gov't | 247 | 0.0 |
Chromosomes, Human, Pair 22/genetics | 16 | 23.0 |
Mutation/genetics | 9 | 0.0 |
Neurofibromatosis 2/diagnosis/genetics | 2 | 100.0 |
Animals | 81 | 0.0 |
Gene Expression Regulation | 2 | 0.0 |
Genotype | 16 | 0.0 |
Mice | 41 | 0.0 |
Mice, Knockout | 2 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 123 | 0.0 |
Brain Stem/*surgery | 8 | 100.0 |
Cochlear Nerve/physiopathology | 2 | 66.0 |
Equipment Design | 2 | 1.0 |
Middle Aged | 126 | 0.0 |
Neurofibromatosis 2/complications | 4 | 100.0 |
*Prostheses and Implants | 3 | 13.0 |
Questionnaires | 2 | 0.0 |
Treatment Outcome | 16 | 0.0 |
Aged | 81 | 0.0 |
Follow-Up Studies | 22 | 0.0 |
English Abstract | 27 | 0.0 |
Child, Preschool | 36 | 0.0 |
Cohort Studies | 5 | 0.0 |
Gene Deletion | 18 | 0.0 |
Infant | 18 | 0.0 |
*Genes, Neurofibromatosis 2 | 97 | 98.0 |
Germ-Line Mutation | 8 | 2.0 |
Loss of Heterozygosity | 19 | 2.0 |
Neurofibromatosis 2/diagnosis/*genetics | 9 | 100.0 |
Adenoviridae/genetics | 3 | 0.0 |
Gene Silencing | 2 | 0.0 |
Genetic Vectors | 3 | 0.0 |
Homozygote | 5 | 0.0 |
Meningeal Neoplasms/*genetics/pathology | 3 | 30.0 |
Meningioma/*genetics/pathology | 3 | 33.0 |
Mice, Mutant Strains | 2 | 0.0 |
Neurofibromin 2/*genetics/metabolism | 3 | 75.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 48 | 0.0 |
Brain Neoplasms/*genetics/pathology | 3 | 4.0 |
DNA, Neoplasm/chemistry/genetics | 2 | 1.0 |
Ependymoma/*genetics/pathology | 3 | 60.0 |
Exons/genetics | 8 | 0.0 |
Neurofibromin 2/*genetics | 3 | 100.0 |
*Chromosome Deletion | 18 | 2.0 |
*Chromosomes, Human, Pair 22 | 42 | 18.0 |
*Hearing | 2 | 28.0 |
Prostheses and Implants | 2 | 18.0 |
Comparative Study | 24 | 0.0 |
Prevalence | 4 | 0.0 |
*Genes, Neurofibromatosis 1 | 5 | 2.0 |
*Genes, Tumor Suppressor | 14 | 1.0 |
Hela Cells | 8 | 0.0 |
Neoplasms/*genetics | 4 | 1.0 |
*RNA Splicing | 4 | 1.0 |
RNA, Messenger/analysis | 6 | 0.0 |
Repressor Proteins/*genetics | 2 | 0.0 |
Temperature | 2 | 0.0 |
Antigens, CD44/metabolism | 2 | 2.0 |
Neurofibromin 2/*metabolism | 6 | 100.0 |
Phosphoproteins/metabolism | 3 | 0.0 |
Phosphorylation | 9 | 0.0 |
Protein Isoforms | 4 | 0.0 |
Rats | 18 | 0.0 |
Age Factors | 11 | 0.0 |
Brain/pathology/physiopathology | 2 | 13.0 |
Gadolinium/diagnostic use | 4 | 25.0 |
Genes, Neurofibromatosis 2/physiology | 4 | 100.0 |
Longitudinal Studies | 2 | 0.0 |
Magnetic Resonance Imaging | 45 | 4.0 |
Mutation/*genetics | 8 | 0.0 |
Neurofibromatosis 2/genetics/*pathology/*physiopathology | 2 | 100.0 |
Neuroma, Acoustic/genetics/*pathology/*physiopathology | 2 | 100.0 |
Severity of Illness Index | 5 | 0.0 |
Time Factors | 6 | 0.0 |
Blotting, Southern | 9 | 0.0 |
Predictive Value of Tests | 2 | 0.0 |
Retrospective Studies | 15 | 0.0 |
Cell Division | 17 | 0.0 |
Cell Line | 19 | 0.0 |
Disease Models, Animal | 7 | 0.0 |
Karyotyping | 9 | 0.0 |
Mice, Nude | 2 | 0.0 |
Neurilemmoma/genetics/*metabolism | 2 | 66.0 |
Neurofibromatosis 2/genetics/*metabolism | 2 | 100.0 |
Reverse Transcriptase Polymerase Chain Reaction | 7 | 0.0 |
Tumor Cells, Cultured | 34 | 0.0 |
Chromosome Mapping | 32 | 0.0 |
Chromosomes, Human, Pair 22/*genetics | 11 | 11.0 |
Pregnancy | 6 | 0.0 |
*Alternative Splicing | 4 | 0.0 |
Base Sequence | 81 | 0.0 |
Binding Sites | 7 | 0.0 |
Molecular Sequence Data | 91 | 0.0 |
Neurofibromatosis 2/*genetics | 71 | 98.0 |
Actins/*metabolism | 2 | 0.0 |
Cells, Cultured | 10 | 0.0 |
Microscopy, Confocal | 3 | 0.0 |
Neurofibromin 2/genetics/*metabolism | 9 | 100.0 |
Recombinant Fusion Proteins/genetics/metabolism | 3 | 0.0 |
DNA, Complementary/metabolism | 2 | 0.0 |
Models, Genetic | 8 | 0.0 |
Mutagenesis, Site-Directed | 4 | 0.0 |
Mutation, Missense | 8 | 1.0 |
Protein Binding | 12 | 0.0 |
Protein Conformation | 2 | 0.0 |
Protein Folding | 2 | 0.0 |
Protein Structure, Tertiary | 8 | 0.0 |
Two-Hybrid System Techniques | 2 | 0.0 |
Blotting, Western | 16 | 0.0 |
Cell Cycle/physiology | 2 | 0.0 |
Flow Cytometry | 3 | 0.0 |
Gene Therapy/*methods | 3 | 0.0 |
Gene Transfer Techniques | 2 | 0.0 |
Green Fluorescent Proteins | 3 | 0.0 |
Luminescent Proteins/metabolism | 2 | 0.0 |
Retroviridae/genetics | 2 | 0.0 |
*Cochlear Implants | 3 | 50.0 |
Neurofibromatosis 2/complications/*surgery | 5 | 100.0 |
Neuroma, Acoustic/complications/*surgery | 3 | 100.0 |
*Radiosurgery | 4 | 33.0 |
Brain Neoplasms | 2 | 14.0 |
Calpain/*metabolism | 2 | 13.0 |
Cell Adhesion | 2 | 0.0 |
*Cell Transformation, Neoplastic | 2 | 0.0 |
Magnetic Resonance Imaging/methods | 3 | 3.0 |
Neuroma, Acoustic/complications/*pathology | 2 | 100.0 |
3T3 Cells | 7 | 0.0 |
Signal Transduction/*physiology | 2 | 0.0 |
Transfection | 18 | 0.0 |
Cytoskeleton/metabolism | 3 | 1.0 |
Models, Biological | 6 | 0.0 |
*Genes, p53 | 2 | 0.0 |
Meningeal Neoplasms/*genetics | 15 | 57.0 |
Meningioma/*genetics | 19 | 57.0 |
*Mutation | 34 | 0.0 |
Neoplasms, Radiation-Induced/*genetics | 2 | 7.0 |
*Tumor Suppressor Proteins | 7 | 0.0 |
Actins/metabolism | 4 | 0.0 |
Precipitin Tests | 5 | 0.0 |
Protein Isoforms/genetics/metabolism | 2 | 1.0 |
Protein Structure, Tertiary/genetics | 5 | 1.0 |
Amino Acid Sequence | 34 | 0.0 |
Mice, Inbred C57BL | 2 | 0.0 |
Sequence Alignment | 7 | 0.0 |
Cell Membrane/metabolism | 4 | 0.0 |
Signal Transduction | 9 | 0.0 |
DNA-Binding Proteins/*genetics | 2 | 0.0 |
Polymerase Chain Reaction/methods | 5 | 0.0 |
Transcription Factors/*genetics | 2 | 0.0 |
Cloning, Molecular | 16 | 0.0 |
Membrane Proteins/*chemistry/genetics/*metabolism | 3 | 16.0 |
Neurofibromin 2 | 86 | 96.0 |
Protein Biosynthesis | 2 | 0.0 |
Protein Isoforms/chemistry/genetics/metabolism | 2 | 4.0 |
Recombinant Fusion Proteins/metabolism | 2 | 0.0 |
Recombinant Proteins/chemistry/metabolism | 2 | 0.0 |
Saccharomyces cerevisiae | 2 | 0.0 |
Sequence Homology, Amino Acid | 12 | 0.0 |
Transcription, Genetic | 8 | 0.0 |
Chromosome Aberrations/*genetics | 3 | 2.0 |
Disease Progression | 7 | 0.0 |
Genes, Tumor Suppressor/genetics | 10 | 6.0 |
Membrane Proteins/genetics | 12 | 3.0 |
*Models, Genetic | 2 | 1.0 |
Neoplasm Recurrence, Local | 3 | 0.0 |
Neurilemmoma/genetics/pathology | 6 | 75.0 |
Phenotype | 31 | 0.0 |
Amino Acid Substitution | 4 | 0.0 |
Cell Division/genetics | 3 | 0.0 |
Neoplasm Proteins/*genetics | 11 | 1.0 |
Neurofibromatosis 2/*genetics/pathology | 10 | 100.0 |
Neurofibromin 2/genetics/metabolism | 3 | 75.0 |
Point Mutation/genetics | 4 | 1.0 |
Aged, 80 and over | 18 | 0.0 |
Meningeal Neoplasms/diagnosis/*genetics/pathology | 2 | 100.0 |
Meningioma/diagnosis/*genetics/pathology | 2 | 100.0 |
Tomography, X-Ray Computed | 12 | 1.0 |
Alternative Splicing | 4 | 0.0 |
Gene Library | 3 | 0.0 |
Glutathione Transferase/metabolism | 3 | 0.0 |
Neurofibromatosis 2/*pathology | 10 | 100.0 |
Cell Differentiation | 3 | 0.0 |
*Genes, Dominant | 2 | 0.0 |
Membrane Proteins/*genetics | 23 | 2.0 |
Nuclear Proteins/*genetics | 2 | 0.0 |
Blotting, Northern | 4 | 0.0 |
Brain Neoplasms/*genetics | 8 | 5.0 |
Genes, Reporter | 2 | 0.0 |
Neurilemmoma/*genetics | 17 | 85.0 |
Radiation Dosage | 2 | 2.0 |
Binding Sites/genetics | 2 | 0.0 |
Cell Division/*physiology | 3 | 1.0 |
*Cytoskeletal Proteins | 8 | 6.0 |
Genes, Tumor Suppressor/*physiology | 2 | 1.0 |
Membrane Proteins/genetics/*metabolism | 8 | 2.0 |
*Neuropeptides | 5 | 4.0 |
Base Sequence/genetics | 4 | 1.0 |
Hand | 2 | 7.0 |
Molecular Biology | 6 | 2.0 |
Point Mutation | 20 | 0.0 |
Soft Tissue Neoplasms/genetics/metabolism/pathology | 2 | 100.0 |
Cell Movement | 3 | 0.0 |
Neurofibromin 1 | 8 | 4.0 |
Chromosome Deletion | 13 | 1.0 |
DNA Primers/chemistry | 6 | 0.0 |
Genes, Neurofibromatosis 2/*genetics | 41 | 100.0 |
Infant, Newborn | 4 | 0.0 |
Microsatellite Repeats | 10 | 0.0 |
Spinal Cord Neoplasms/*genetics | 6 | 75.0 |
Chromosomes, Human, Pair 1/*genetics | 2 | 0.0 |
*Loss of Heterozygosity | 11 | 2.0 |
Cell Communication | 2 | 0.0 |
Neurofibromatosis 1/*genetics/pathology | 2 | 9.0 |
Proto-Oncogene Protein p21(ras)/metabolism | 2 | 2.0 |
DNA Primers | 16 | 0.0 |
*Gene Expression Regulation, Neoplastic | 5 | 0.0 |
*Cochlear Nucleus | 2 | 100.0 |
Evoked Potentials, Auditory, Brain Stem | 9 | 37.0 |
Hearing Loss, Central/complications/*surgery | 3 | 100.0 |
Lipreading | 2 | 100.0 |
*Prosthesis Implantation | 2 | 66.0 |
Speech Perception | 3 | 42.0 |
Prosthesis Implantation/*methods | 2 | 66.0 |
Age of Onset | 11 | 0.0 |
Audiometry, Evoked Response | 2 | 50.0 |
Audiometry, Pure-Tone | 7 | 17.0 |
Genetic Screening | 8 | 0.0 |
Prospective Studies | 4 | 0.0 |
Risk Factors | 6 | 0.0 |
Codon, Nonsense | 2 | 1.0 |
Frameshift Mutation | 11 | 2.0 |
*Magnetic Resonance Imaging | 4 | 2.0 |
Codon, Terminator | 2 | 3.0 |
Heterozygote | 8 | 0.0 |
Lymphocytes/metabolism | 3 | 1.0 |
Restriction Mapping | 8 | 0.0 |
Sequence Deletion | 21 | 1.0 |
Neurofibromatosis 2/genetics/metabolism/*physiopathology | 2 | 100.0 |
Membrane Proteins/*metabolism | 7 | 1.0 |
Meningeal Neoplasms/*genetics/metabolism | 2 | 66.0 |
Meningioma/*genetics/metabolism | 2 | 50.0 |
Genes, Neurofibromatosis 2/*physiology | 6 | 100.0 |
*Chromosome Aberrations | 6 | 1.0 |
*Chromosome Disorders | 2 | 2.0 |
DNA/genetics | 3 | 0.0 |
Haplotypes | 5 | 0.0 |
*Mosaicism | 4 | 7.0 |
Pedigree | 32 | 0.0 |
*Chromosome Mapping | 7 | 0.0 |
*Chromosomes, Human, Pair 14 | 2 | 1.0 |
Genetic Markers | 22 | 0.0 |
Hearing Disorders/diagnosis/etiology | 2 | 100.0 |
Vestibule/pathology | 2 | 100.0 |
Deafness/etiology | 6 | 100.0 |
Neuroma, Acoustic/pathology/*surgery | 3 | 75.0 |
Parents | 3 | 4.0 |
Audiometry | 2 | 4.0 |
Regression Analysis | 2 | 0.0 |
Cell Membrane/physiology | 2 | 1.0 |
Phosphoproteins/*metabolism | 2 | 0.0 |
*Sodium-Hydrogen Antiporter | 2 | 18.0 |
Gene Expression Regulation, Neoplastic/physiology | 4 | 2.0 |
Reference Values | 4 | 0.0 |
Schwann Cells/*drug effects/physiology | 2 | 100.0 |
Genes, Tumor Suppressor | 12 | 1.0 |
Genetic Counseling | 3 | 1.0 |
Diagnosis, Differential | 15 | 0.0 |
Neurofibromatosis 2/*complications/diagnosis/surgery | 2 | 100.0 |
Radiosurgery | 2 | 40.0 |
Neurilemmoma/genetics/metabolism | 2 | 66.0 |
*Alleles | 4 | 0.0 |
Mice, Transgenic | 4 | 0.0 |
Neurilemmoma/genetics | 4 | 50.0 |
Survival Analysis | 3 | 0.0 |
Neurofibromatosis 2/*complications | 6 | 100.0 |
DNA Mutational Analysis/*methods | 2 | 1.0 |
Introns | 6 | 0.0 |
Neoplasm Proteins/genetics | 8 | 1.0 |
Meningioma/genetics | 8 | 57.0 |
DNA/chemistry/genetics | 2 | 0.0 |
Sequence Homology, Nucleic Acid | 2 | 0.0 |
Skin Neoplasms/*genetics | 2 | 1.0 |
Genes, Neurofibromatosis 2/genetics | 11 | 84.0 |
Immunoblotting | 4 | 0.0 |
Membrane Proteins/*analysis | 2 | 2.0 |
Preoperative Care | 2 | 1.0 |
Genes, Neurofibromatosis 2/*genetics/physiology | 2 | 100.0 |
Point Mutation/*genetics | 3 | 1.0 |
Solubility | 2 | 0.0 |
Diseases in Twins/*genetics | 4 | 14.0 |
Patient Selection | 2 | 1.0 |
Twins, Monozygotic/*genetics | 2 | 10.0 |
RNA Splicing | 5 | 0.0 |
Astrocytoma/*genetics | 2 | 4.0 |
DNA, Neoplasm/genetics | 12 | 1.0 |
Glioblastoma/genetics | 2 | 6.0 |
Glioma/*genetics | 3 | 3.0 |
Microsatellite Repeats/genetics | 2 | 0.0 |
Schwann Cells/*pathology | 3 | 33.0 |
*Trigeminal Nerve | 2 | 66.0 |
Finland | 2 | 0.0 |
Incidence | 6 | 0.0 |
Registries | 4 | 1.0 |
Fundus Oculi | 3 | 3.0 |
Neurofibromatosis 2/diagnosis | 2 | 100.0 |
Visual Acuity | 3 | 1.0 |
*Polymorphism, Single-Stranded Conformational | 3 | 2.0 |
Loss of Heterozygosity/genetics | 5 | 3.0 |
Facial Paralysis/etiology | 4 | 100.0 |
Neurofibromatosis 2/complications/*diagnosis/genetics | 2 | 100.0 |
Prognosis | 9 | 0.0 |
Skin Neoplasms/diagnosis | 2 | 50.0 |
DNA, Complementary | 2 | 0.0 |
Membrane Proteins/analysis/*genetics | 3 | 16.0 |
Reverse Transcriptase Polymerase Chain Reaction/methods | 2 | 0.0 |
Family Health | 3 | 0.0 |
Spinal Cord/pathology | 3 | 4.0 |
Neurofibromatosis 2/*surgery | 3 | 100.0 |
DNA Mutational Analysis/methods | 2 | 0.0 |
DNA Repair/genetics | 2 | 1.0 |
Evaluation Studies | 2 | 0.0 |
Mosaicism | 4 | 5.0 |
Loss of Heterozygosity/*genetics | 3 | 3.0 |
Membrane Proteins/biosynthesis/genetics | 3 | 7.0 |
Mesothelioma/*genetics | 6 | 31.0 |
Neurilemmoma/*complications | 2 | 66.0 |
Gene Expression | 8 | 0.0 |
Pseudopodia/metabolism | 2 | 6.0 |
Tissue Distribution | 3 | 0.0 |
Variation (Genetics) | 3 | 0.0 |
Chromosome Disorders | 8 | 2.0 |
Protein p16/genetics | 2 | 2.0 |
DNA/blood | 3 | 1.0 |
Neurofibromatosis 2/genetics | 6 | 66.0 |
Polymorphism, Restriction Fragment Length | 10 | 0.0 |
Apoptosis | 2 | 0.0 |
Up-Regulation | 3 | 0.0 |
Nervous System Neoplasms/*genetics | 3 | 27.0 |
Chromosome Aberrations/genetics | 4 | 3.0 |
Neoplasms, Multiple Primary/*genetics | 2 | 5.0 |
*Heterozygote | 4 | 1.0 |
*Polymorphism, Genetic | 3 | 0.0 |
Membrane Proteins/genetics/*physiology | 2 | 3.0 |
Mutagenesis | 2 | 0.0 |
Rabbits | 2 | 0.0 |
DNA-Binding Proteins/genetics | 3 | 0.0 |
Transcription Factors/genetics | 4 | 0.0 |
Neurofibromatosis 1/pathology | 2 | 40.0 |
Tinnitus/etiology | 2 | 100.0 |
Neoplasm Staging | 2 | 0.0 |
Glioma | 3 | 4.0 |
Neoplasm Proteins/metabolism | 4 | 1.0 |
Neurilemmoma/metabolism/*pathology | 2 | 28.0 |
Neurofibromatosis 2/metabolism/*pathology | 2 | 100.0 |
Lung Neoplasms/*genetics | 2 | 0.0 |
Phosphoproteins/genetics | 2 | 1.0 |
Sequence Analysis | 2 | 0.0 |
*Germ-Line Mutation | 5 | 1.0 |
Neurofibromatoses/*genetics | 2 | 22.0 |
Genes, Dominant/genetics | 2 | 1.0 |
Genetic Predisposition to Disease/genetics | 2 | 0.0 |
Neurilemmoma/*diagnosis/genetics | 2 | 100.0 |
*Genes, p16 | 2 | 2.0 |
Heterozygote Detection | 4 | 0.0 |
*Chromosomes, Human, Pair 1 | 2 | 0.0 |
Cell Survival | 2 | 0.0 |
Cytoskeleton/ultrastructure | 2 | 8.0 |
Brain Neoplasms/genetics/pathology | 2 | 22.0 |
Membrane Proteins/chemistry/*genetics/*metabolism | 2 | 13.0 |
*Point Mutation | 8 | 0.0 |
*Sequence Deletion | 3 | 0.0 |
Spinal Cord Neoplasms/genetics/pathology | 2 | 100.0 |
Neurilemmoma/*pathology | 3 | 42.0 |
Patch-Clamp Techniques | 2 | 0.0 |
Neurofibromatosis 2/complications/diagnosis | 2 | 66.0 |
Syndrome | 2 | 0.0 |
Conserved Sequence | 2 | 0.0 |
*Microfilament Proteins | 5 | 10.0 |
Recombinant Fusion Proteins/biosynthesis/metabolism | 2 | 2.0 |
Cell Division/physiology | 3 | 0.0 |
Brain Neoplasms/*metabolism | 4 | 5.0 |
Enzyme Activation | 2 | 0.0 |
Meningioma/*metabolism | 4 | 21.0 |
Neurilemmoma/*metabolism | 3 | 50.0 |
RNA, Messenger/biosynthesis | 2 | 0.0 |
Genes, Tumor Suppressor/*genetics | 3 | 0.0 |
Cerebellar Neoplasms/*pathology | 2 | 33.0 |
Neuroma, Acoustic/*pathology | 2 | 100.0 |
Contrast Media | 3 | 5.0 |
Brain Neoplasms/genetics | 2 | 11.0 |
DNA Transposable Elements | 2 | 1.0 |
Family | 3 | 0.0 |
Blood Proteins/analysis | 2 | 1.0 |
Cell Membrane/chemistry | 2 | 1.0 |
Cytoskeleton/*chemistry | 2 | 33.0 |
Recombinant Fusion Proteins | 2 | 0.0 |
Genetic Markers/genetics | 5 | 1.0 |
Chromosome Aberrations | 6 | 1.0 |
Brain/metabolism | 4 | 0.0 |
Cattle | 2 | 0.0 |
Neurilemmoma | 2 | 66.0 |
Hamsters | 4 | 0.0 |
Breast Neoplasms/*genetics | 4 | 0.0 |
Gene Expression Regulation, Neoplastic | 4 | 0.0 |
*Transcription, Genetic | 3 | 0.0 |
Neurofibromatosis 2/genetics/*pathology | 2 | 100.0 |
Skin/pathology | 2 | 0.0 |
Neurofibromatosis 2/*diagnosis | 3 | 100.0 |
Gene Amplification | 2 | 0.0 |
Nucleic Acid Hybridization | 6 | 0.0 |
Haplotypes/genetics | 2 | 0.0 |
Spinal Neoplasms/genetics | 2 | 50.0 |
Protein Binding/physiology | 2 | 0.0 |
*Linkage (Genetics) | 3 | 0.0 |
Nucleic Acid Heteroduplexes | 2 | 4.0 |
Codon/genetics | 5 | 1.0 |
Cranial Nerve Neoplasms/*genetics | 3 | 100.0 |
Neuroma, Acoustic/*genetics | 10 | 90.0 |
Fluorescent Antibody Technique | 3 | 0.0 |
Proteins/*metabolism | 2 | 0.0 |
Chromosomes, Human, Pair 22 | 24 | 15.0 |
Neoplasm Proteins | 2 | 6.0 |
Neuroma, Acoustic/diagnosis/physiopathology/surgery | 2 | 100.0 |
*Ring Chromosomes | 3 | 9.0 |
Ependymoma/*metabolism | 2 | 40.0 |
Meningeal Neoplasms/*metabolism | 2 | 11.0 |
Fatal Outcome | 3 | 0.0 |
Linkage (Genetics) | 8 | 0.0 |
Lod Score | 5 | 0.0 |
Cell Line, Tumor | 4 | 0.0 |
Detergents/pharmacology | 2 | 1.0 |
NIH 3T3 Cells | 2 | 0.0 |
Cataract/etiology | 2 | 25.0 |
Chromosomes, Human, Pair 17 | 7 | 2.0 |
Genes, Neurofibromatosis 1/genetics | 2 | 15.0 |
Proteins/genetics | 4 | 0.0 |
Neurilemmoma/metabolism | 2 | 40.0 |
DNA | 4 | 0.0 |
Central Nervous System Neoplasms/*genetics | 3 | 21.0 |
*DNA Methylation | 2 | 0.0 |
Ependymoma/*genetics | 6 | 54.0 |
Organ Specificity | 3 | 0.0 |
RNA, Neoplasm/analysis | 2 | 0.0 |
Neuroma, Acoustic/diagnosis | 2 | 66.0 |
*Chromosomes, Human, Pair 17 | 3 | 0.0 |
Cataract/genetics | 3 | 27.0 |
*Phenotype | 2 | 0.0 |
DNA, Neoplasm/genetics/isolation & purification | 2 | 1.0 |
DNA, Complementary/genetics | 2 | 0.0 |
Neurilemmoma/pathology | 2 | 28.0 |
Immunoenzyme Techniques | 6 | 0.0 |
Tumor Markers, Biological/metabolism | 3 | 0.0 |
Brain/pathology | 4 | 1.0 |
Neurologic Examination | 2 | 1.0 |
Survival Rate | 2 | 0.0 |
Ependymoma/genetics | 2 | 22.0 |
Glioma/genetics | 2 | 9.0 |
Meningeal Neoplasms/genetics | 4 | 66.0 |
Neuroma, Acoustic/genetics | 5 | 100.0 |
Colorectal Neoplasms/*genetics | 4 | 1.0 |
*Translocation, Genetic | 5 | 0.0 |
Cell Transformation, Neoplastic/genetics | 3 | 1.0 |
Neurofibromatosis 2/diagnosis/physiopathology/*surgery | 2 | 100.0 |
DNA, Neoplasm/*analysis | 2 | 1.0 |
Repetitive Sequences, Nucleic Acid | 4 | 0.0 |
DNA/analysis | 2 | 0.0 |
*Vestibular Nerve | 2 | 66.0 |
*Gene Deletion | 6 | 0.0 |
*Gene Expression Regulation, Developmental | 2 | 0.0 |
In Situ Hybridization | 3 | 0.0 |
Membrane Proteins/biosynthesis/*genetics | 3 | 6.0 |
Peptides/chemistry/immunology | 2 | 5.0 |
DNA, Satellite/genetics | 2 | 1.0 |
Liver Neoplasms/*genetics | 2 | 1.0 |
Chromosomes, Human, Pair 11 | 3 | 0.0 |
Oncogenes | 2 | 0.0 |
Down-Regulation | 2 | 0.0 |
Dyes/pharmacology | 2 | 2.0 |
Multigene Family | 2 | 0.0 |
Codon | 3 | 0.0 |
Soft Tissue Neoplasms/*genetics | 2 | 7.0 |
*Exons | 2 | 0.0 |
RNA, Messenger/genetics | 2 | 0.0 |
Neurofibromatosis 2/*metabolism | 2 | 100.0 |
DNA, Neoplasm/*genetics | 2 | 0.0 |
Genes, Dominant | 2 | 0.0 |
DNA, Single-Stranded/genetics | 3 | 8.0 |
Nucleic Acid Conformation | 2 | 0.0 |
Membrane Proteins/chemistry/*genetics | 3 | 4.0 |
RNA, Messenger/*genetics | 2 | 0.0 |
*Chromosomes, Human, Pair 4 | 2 | 0.0 |
Oligonucleotide Probes | 3 | 0.0 |
Meningeal Neoplasms/classification/*genetics/pathology | 2 | 100.0 |
Meningioma/classification/*genetics/pathology | 2 | 100.0 |
Neurofibromatosis 1/*genetics | 5 | 2.0 |
Neuroma, Acoustic/*pathology/*surgery | 3 | 100.0 |
Chromosomes, Human, Pair 22/*ultrastructure | 3 | 37.0 |
Electrophoresis, Gel, Pulsed-Field | 2 | 0.0 |
Hybrid Cells | 4 | 0.0 |
Alternative Splicing/genetics | 2 | 1.0 |
Neoplasm Proteins/chemistry/*genetics | 3 | 10.0 |
Protein Structure, Secondary | 2 | 0.0 |
Phylogeny | 2 | 0.0 |
Combined Modality Therapy | 2 | 0.0 |
Chronic Disease | 2 | 0.0 |
DNA Probes | 4 | 0.0 |
*Genetic Markers | 3 | 0.0 |
Cosmids | 3 | 0.0 |
Acoustic Stimulation | 2 | 2.0 |
Electrodes, Implanted | 2 | 13.0 |
Gadolinium DTPA | 2 | 16.0 |
Organometallic Compounds/diagnostic use | 2 | 16.0 |
Pentetic Acid/diagnostic use | 2 | 15.0 |
Great Britain/epidemiology | 2 | 1.0 |
Sex Factors | 2 | 0.0 |
Testicular Neoplasms/genetics | 2 | 28.0 |
Neurofibroma/*genetics | 2 | 13.0 |
Neurofibromin 2/genetics | 3 | 100.0 |
Genetic Markers/analysis | 2 | 7.0 |
Disease-Free Survival | 2 | 0.0 |
*Neoplasm Recurrence, Local | 2 | 4.0 |
Gastrointestinal Neoplasms/*genetics/metabolism/pathology | 2 | 28.0 |
Models, Statistical | 2 | 1.0 |
Cell Division/drug effects | 2 | 0.0 |
Neurofibromin 2/metabolism | 2 | 100.0 |
